News

First patient enrollment in MASCOT registry represents major milestone for COMBO™ Dual Therapy Stent and OrbusNeich’s clinical program.

more...


COMBO Dual Therapy Stent: A Long term Solution to Vessel Restoration. Latest results further support excellent healing benefits of World’s first and only Dual Therapy Stent.

more...

MASCOT Registry


First patient enrollment in MASCOT registry represents major milestone for COMBO™ Dual Therapy Stent.


2,500-patient, 50-center study is the largest post-marketing registry on the safety and effectiveness of the COMBO Stent.


HONG KONG, July 16, 2014 – OrbusNeich today announced that the first patient has been enrolled in the Multinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) post-marketing registry.


Read more...

COMBO Dual Therapy Stent: A Long term Solution to Vessel Restoration.


Latest results further support excellent healing benefits of World’s first and only Dual Therapy Stent .


Genoa, Italy, 17th October, 2014 - Latest data presented on the COMBO Dual Therapy Stent, provides further evidence to support the long-term safety and efficacy of the stent in the treatment of coronary artery disease.


Read more...